Clinical Research Directory
Browse clinical research sites, groups, and studies.
Venlafaxine for Non-specific Low Back Pain
Sponsor: Beijing Tiantan Hospital
Summary
Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.
Official title: Efficacy and Safety of Venlafaxine in the Treatment of Non-specific Low Back Pain
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
228
Start Date
2026-09-01
Completion Date
2028-12-30
Last Updated
2026-07-30
Healthy Volunteers
No
Interventions
Control Group
Participants in the control group will receive routine clinical care for chronic nonspecific low back pain.
Venlafaxine group
Venlafaxine is administered orally at a starting dose of 75 mg once daily. In patients with insufficient pain response who can tolerate the adverse effects, the dose may be carefully titrated up to 225 mg once daily. The maintenance period is 3 months.
Locations (1)
Beijing Tiantan Hospital
Beijing, China, China